LICENSE AGREEMENT
Exhibit 10.1
This License Agreement (“Agreement”) is entered into as of the Effective Date by and between Immunovative Therapies Ltd., an Israeli corporation with a principal place of business at Malcha Technology Park, Building Xx. 0, Xxxxx Xxxxx, Xxxxxxxxx, Xxxxxx, 00000 (“Licensor”); and Novo Energies Corporation a Florida Corporation with a principal place of business at 000 Xxxx xx Xxxxx x'Xxxx, Xxxxx 00, Xxxxxxxx, Xxxxxx, Xxxxxx X0X 0X0 (“Licensee”).
When used in this Agreement, the following terms (whether used in the singular or plural or possessive) shall have the following meanings:
1.1 “Effective Date” means the date of the last signature set forth below for executing this Agreement.
1.2 “Patent Rights” means the listed granted patents and pending patent applications (including PCT applications) shown on Schedule A (showing country of granted patent or pending applications) attached hereto, and all patents and patent applications not listed and related thereto (e.g., divisions, continuations, continuations-in-part, reissues, reexaminations, related international or foreign counterparts and extensions thereof) and includes any future patents and patent applications solely or jointly owned by Licensor, or licensed by Licensor or any of its subsidiaries, with the right to sublicense.
1.3 “Licensed Product” means a product, system, process, technique, or composition, that is within the scope covered by one or more patent claims of the Patent Rights (see below). The Licensed Products currently in clinical development are known as "AlloStimTM" and "AlloVaxTM" which are herein also referred to as "Product Candidates" or "Products". For example purposes, laboratory testing services developed to predict or measure a response to a Product Candidate, such as the biomarker, IL-12 is within the definition of a Licensed Product. An automated device designed to formulate living cell products at a physician's office or clinic is within the definition of a Licensed Product.
1.4 “Commercialization”, “Commercializing”, “Commercialized”, and the like means obtaining regulatory approval to introduce a Licensed Product into a territory for sale, market, offer to sell, sell, and import the Licensed Product and taking measures to successfully market and sell the Products in such territory, such measures include, but are not limited to, marketing efforts, physician training and education, product sales, and offers to sell.
1.5 “Confidential Information” means all non-public confidential and proprietary information provided to Licensor by Licensee or to Licensee by Licensor including, but not limited to, information related to research, marketing, or finance, patient names, treatments and treatment plans, patient diagnoses, medical records, protocols, clinical data, hardware, machines, processes, material compositions, material processes, encryptions, software code, algorithms, formulas, ideas, inventions, developments, improvements, future research, trade secrets, designs, drawings, samples, media, works of authorship, know how, business information, contracts and contractual relationships, sales and marketing strategies, sales leads, business plans, regulatory submissions, correspondence and strategies, employee manuals, policies, procedures, standard operating procedures and forms for GMP operations or other internal operations, vendor lists, presentations, business methods, product functionality, services, data, customers, markets, competitive analysis, databases, formats, methodologies, applications, payment, delivery, inspection and audit procedures, formulas and results, employee performance records.
1.6 “Dollar” means the U.S. dollar. All monetary amounts recited in this Agreement are based on United States (U.S.) currency.
1.7 “Know How” means all technical and other information which is not in the public domain (other than as a result of a breach of confidence), including but not limited to, information comprising or relating to concepts, discoveries, data, designs, formulae, ideas, inventions, methods, models, procedures, designs for experiments and tests and results of experimentation and testing, processes, specifications and techniques, laboratory records, clinical data, manufacturing and quality control data, trade secrets and Confidential Information intended to remain as such, whether or not protected by any Patent Rights or any applications for such rights.
1.8 “Intellectual Property Rights” "IPR" shall mean all intellectual property rights including, without limitation, Patent Rights, Know How, all inventions, discoveries and other technical information that are not yet subject of a patent application, Confidential Information and trade secrets, whether or not patentable, patent applications, patents, original works of authorship, whether or not copyrightable, all copyrights including morale, mask work rights, rights on databases, trademarks, trade secrets, know how, and all other proprietary rights in whatever form or medium, which may be recognized under any jurisdiction, in each case on a worldwide basis, together with all improvements, revisions, extensions, reexaminations, translations, adaptations, derivative work, and combinations thereof.
1.9 “Fully-Diluted Basis” shall mean the assumption that all options, warrants or other convertible securities or instruments or other rights to acquire Common Stock or any other existing or future classes of capital stock have been exercised or converted, as applicable, in full, regardless of whether any such options, warrants, convertible securities or instruments or other rights are then vested or exercisable or convertible in accordance with their terms.
2.2.2 Sublicense Agreement: Licensee shall have the right to negotiate sublicense agreements provided any such agreement shall contain, inter alia, confidentiality, non-compete and indemnity protections at least as severe as those imposed on Licensee herein and such other applicable requirements of this Agreement, including a definition of the Licensed Product under the Patent Rights, and the indication and territory allowed to be developed for Commercialization. The final agreement, however, shall be subject to the prior written approval of the Licensor, which may be denied at its sole discretion. Licensee shall at all times remain liable towards Licensor for any and all breaches of this Agreement by any of the Sublicensees.
2.2.3 Sublicense Fees: Licensee shall have the right to charge fees to a sublicensee under Paragraph 2.2, such as monthly fees, royalty payments, milestone payments, equity sales or exchanges and the like, as well as define a transfer price for delivery of a Licensed Product into the territory of the Sublicensee for the defined Product Candidate under the Patent Rights. Such payment terms shall be detailed in the agreement subject to paragraph 2.2.2.
2.2.4 Distribution of Sublicense Fees: The manner and mechanism for distribution of Sublicense Fees under 2.2.3 above shall be described in a separate agreement between Licensee and Licensor for each sublicense. Said separate agreement under this paragraph must be executed prior to Licensee signing a Sublicense Agreement pursuant to 2.2.2 above.
2.8 Licensor Roles and Obligations. Licensor shall be responsible for the continued research and development of the Licensed Products, the conduct of the Clinical Trial, manufacturing, formulation, packaging and shipping of any Licensed Products, patent prosecution and regulatory filings pertaining to Licensed Products with the FDA or the equivalent regulatory bodies in other applicable jurisdictions. All Intellectual Property Rights, raw data and any Know-How obtained as a result or in the course of conduct of the Clinical Trial or otherwise throughout the term of this Agreement shall be deemed proprietary and Confidential Information of the Licensor, subject to the applicable provisions hereof.
|
3.2.1
|
Upfront Payment. A payment of four hundred and fifty thousand dollars ($450,000) shall be made upon the Effective Date of this Agreement;
|
|
3.2.2
|
Minimum Monthly Payment. Throughout the term commencing on the later of: (i) 90 days after the Effective Date; and (ii) the date upon which Licensor submits to a peer-reviewed journal a manuscript for publication describing the results of the Phase I/II clinical trial conducted pursuant to IND 13,936l; and ending upon the aggregate payment of $10 million, Licensee shall pay Licensor a minimum monthly maintenance fee of one hundred and fifty thousand dollars ($150,000), payable upfront no later than by the 5th day of each month. Any additional payments made pursuant to 3.2.4 that are in excess of amounts due under Sections 3.2.1 and 3.2.2 may be credited towards future amounts due under Section 3.2.2;
|
|
3.2.3
|
Clinical Trial Payment. A minimum $2 million payment shall be made within 90 days after receiving Regulatory Notice to conduct the first Clinical Trial. Licensor shall use these funds only for direct costs of supporting the Clinical Trial, including, but not limited to, costs to manufacture, formulate and ship clinical grade product and placebo, fees to clinical research organization (CRO), cost of physicians, nurses, data managers and clinical administrative personnel, costs of facilities dedicated for use in performing the Clinical Trial, and immunological monitoring costs.
|
|
3.2.4
|
Additional Payments. Other than the set payment requirements outlined in paragraphs 3.2.1, 3.2.2 and 3.2.3, the remaining License Cost payments can be made at any time or schedule over the period beginning upon the Effective Date of this Agreement and continuing until a date 24 months after receiving Regulatory Notice (the "Period").
|
|
3.2.5
|
Payment Schedule. All payment requirements under this paragraph 3 will end when the total accumulated payments made during the Period to Licensor reaches $10 million. While the additional payments pursuant to paragraph 3.2.4 above can be made at any time or schedule, the intent of this Agreement is that Licensee will endeavor to pay the License Cost as soon as practical during the Period. Accordingly, Licensee agrees to transfer a portion of funds it has raised to the Licensor as soon as practical each time after the funds have been deposited and released to Licensee, while agreeing only to retain enough of such funds from each investment round reasonably calculated to support the operations of the Licensee. .
|
4.3.1 Additions to Licensee Ownership. Any funds paid to Licensor by Licensee in excess of the License Cost until consummation of the Merger shall be credited to the Licensee thus increasing Licensee's ownership in the merged entity. Calculation of the increase shall be based upon an assumption of a $40 million post-money valuation of the merged entity upon payment of $10 million by the Licensee and a 75/25 Licensor/Licensee share distribution ratio on a Fully Diluted Basis. Accordingly, by way of example, if Licensee paid $12 million at a post-money value of $40 million, the post-money value of the entity would increase from $40 million to $42 million. The $12 million investment divided by the $42 million valuation results in an increase in the ownership of the Licensee in the entity from 25% to 28.57%. If contributed funds are in the form of a grant or other form of compensation, to the extent the funds were used by Licensor to defray the direct costs of successfully completing the Clinical Trial, the funds will be credited to the Licensee toward payment of the License Cost.
Similarly, if the Licensor has any debt, liability or other form of indebtedness (excluding any liabilities owed to patent attorney or for patent maintenance fees) at the time of the Merger these shall be deducted from the Licensor and credited to the Licensee. For example, assuming the Licensee paid $10 million and the Licensor has $ 1 million in debts, the post-money value would be decreased to $39 million. The $10 million divided by the $39 million valuation would increase the ownership of the Licensee in the merged entity from 25% to 25.64%.
4.3.2 Subtractions to Licensee Ownership: Any equity or grant funding obtained by Licensor from third parties after the Effective Date and until consummation of the Merger shall be credited to the Licensor thus increasing Licensor's ownership in the merged entity and decreasing Licensee's ownership. For example, assuming the Licensee paid the full $10 million at the time of Merger and the Licensor raised $1 million after the Effective date, the post-money valuation would increase to $41 million. The $10 million investment of the Licensee divided by the $41 million valuation results in a decrease in the ownership of the Licensee in the merged entity from 25% to 24.39%.
Similarly, any debt, liability or other forms of indebtedness of Licensee at the time of the Merger shall be deducted and credited to Licensor thus increasing Licensor's ownership in the merged entity and decreasing Licensee's ownership. For example, assuming the Licensee paid the full $10 million and had $1 million in debt at the time of the merger. The post-money valuation of the entity would be $39 million. The $10 million investment would be adjusted to $9 million for purposes of determining the ownership percentage. The $9 million divided by $39 million results in a decrease in the ownership of the Licensee in the merged entity from 25% to 23.1%.
4.4 Conditions Requiring Merger. Provided that the Licensee has paid the License Cost in full within the Period, consummation of the Merger shall occur within 90 days of the successful completion of the Clinical Trial. Both Licensee and Licensor shall agree to cooperate to effectuate the Merger in a timely manner. As, depending on the structure of the Merger, Licensee will likely be required to file a current report on Form 8-K reporting the Merger that is compliant with, and provides the information required under, Items 1.01, 3.02, 5.01, 5.06, 9.01 and any other applicable Item of Form 8-K (the “Super 8-K”) including the necessary financial information, Licensor agrees to provide Licensee with all information regarding Licensor and its property and the Products required for the Super 8-K within 60 days of the successful completion of the Clinical Trial (which information shall include all necessary audited financial information).
4.5 License Payment and Non-Completion of Clinical Trial. If the Licensee has paid the License Cost in full within the Period and Licensor has not successfully completed the Clinical Trial, the Merger may be consummated with the agreement of the Licensor and Licensee. If the Licensor or Licensee agree to Merge, the provisions of Section 4.4 shall apply as if the date of notification of this choice were the date of the successful completion of the Clinical Trial. As long as the Licensee has paid the License Cost in full within the Period and does not choose this approach, Licensee shall retain the license granted in paragraph 2 above.
4.6 Spending License Fee and Non-Completion of Clinical Trial. If Licensee has paid the License Cost in full within the Period and Licensor has spent the $10 million without successfully completing the Clinical Trial, the Merger may be consummated with the agreement of the Licensor and Licensee. If the two parties will proceed with the Merger, the provisions of Section 4.4 shall apply as if the date of notification of this choice were the date of the successful completion of the Clinical Trial. As long as the Licensee has paid the License Cost in full within the Period but elects not choose this approach, Licensee shall retain the license granted in paragraph 2 above. If Licensee provides any additional payments to Licensor in order to successfully complete the Clinical Trial, Licensor shall issue ordinary shares to Licensee, the number of shares to be calculated based upon a $40 million pre-money valuation (Fully Diluted).
4.7 Partial Payment of License Fee. If the Clinical Trial has been successfully completed but the Licensee has not completely paid the License Cost in full within the Period, the Merger can be consummated with the agreement of the Licensor and Licensee. If the Licensor or Licensee elects not to consummate the Merger, Licensor shall issue ordinary shares to Licensee for the amount paid by Licensee to Licensor. The number of shares issued will be calculated based upon a $30 million pre-money market value (Fully Diluted). Upon issuance of these shares, this Agreement will terminate in accordance with the provisions of paragraph 10 below and Licensee shall not retain any of the license rights described in paragraph 2 above.
4.8 Modifications to 4.6 and 4.7. If Licensor has any debts (with the exception of patent related debts and trade liabilities) at the time ordinary shares are to be issued pursuant to Section 4.6 or 4.7, then the valuation of the Licensor set out in each of Section 4.6 and 4.7 shall be reduced by the amount of that outstanding debt when calculating the number of shares to issue. Additionally, if Licensee is to receive ordinary shares under Sections 4.6 or 4.7 and if Licensor has any other class of shares of capital stock outstanding that converts to ordinary shares, then the number of ordinary shares Licensee shall receive as calculated in Sections 4.6 to 4.8 shall represent the percentage of shares that shall equal (on a fully-diluted basis) the number of ordinary shares that will be outstanding upon the exercise of all classes of outstanding shares.
5.1 Best Efforts for Regulatory Approval: Licensor and Licensee shall collaborate to achieve U.S. and international regulatory approvals for the Commercialization of the Licensed Products. This includes performing clinical trials on the Licensed Products.
6.2 Intellectual Property Ownership: Licensee acknowledges and agrees that all Intellectual Property Rights (including, for example, inventions, proprietary and non-proprietary information, specifications, requirements, and improvements, whether patentable or not, and works of authorship) and any Know How evidenced by or embodied in and/or connected/related/attached to the Licensed Products or that is conceived or developed during the term or in the course of the performance of this Agreement or the conduct of the Clinical Trials, the regulatory and Commercialization efforts under Paragraphs 5.1 and 5.2 by Licensee, and/or by any third party, is the sole and exclusive property of Licensor. Licensee and any of Licensee’s Personnel and any sublicensed third-party will promptly disclose the creation of such intellectual property to Licensor and, upon written request, assign to Licensor any and all of their intellectual property rights to such intellectual property and shall execute, and shall assure that Licensee's Personnel execute all such documents and do all such other acts as Licensor may reasonably require in order to vest fully and effectively all such Intellectual Property Rights and Know How with Licensor.
Any documentation, information, data, or materials provided to Licensee or anyone on its behalf by Licensor under this Agreement and any Know-How or Intellectual Property Rights embodied therein or pertaining thereto shall be the sole and exclusive property of Licensor
All Intellectual Property Rights and Know How owned by or licensed to Licensor prior to and after the date of this Agreement are and shall remain the sole and exclusive property of Licensor.
Licensee and any of its Personnel, jointly and severally, shall refrain from making any use whatsoever of the Licensor Intellectual Property Rights or Know How, other than under the License granted herein.
6.4 Public Reporting Obligations: It is recognized that Licensee will have obligations under the federal securities laws to disclose business and financial information on an ongoing basis. For example, annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K for a number of specified events and must comply with a variety of other disclosure requirements. However, Licensee still has a duty to protect Licensor's Confidential Information and is not required to disclose confidential technical or business information to the public. In order to protect Licensor's Confidential Information, Licensee agrees to allow Licensor to review all public filings (eg., 10K, 10Q, 8K, etc. – excluding any filings for automatic extensions or on Form D) at least five (5) business days prior to submission and all public press releases at least three (3) days prior to release. Licensee agrees not to include information in any public filing that Licensor reasonably objects to on grounds that the document contains disclosure of Confidential Information. If Licensee disagrees with Licensor and determines that it has a legal duty to disclose disputed information, then such information will be submitted to the applicable regulatory authority clearly marked as confidential for a determination if the disputed information requires public disclosure. In no case will Licensee disclose information to the public which Licensor reasonably states is Confidential Information without a ruling from a regulatory authority or court of competent jurisdiction.
7.2 Adequacy of License. The Patent Rights includes all knowledge necessary to enable Licensee and the sublicensee’s to Commercialize the Licensed Products.
7.3 No Infringement. There is no claim pending or threatened against Licensor or any other person alleging that any of the Patent Rights or the Commercialization of any of the Licensed Products, infringes or conflicts with, or will infringe or conflict with, any proprietary right or other right of any person. To the best of Licensor's knowledge, there is no existing or potential infringement of any of the Patent Rights or Licensed Products. None of the Patent Rights or Licensed Products incorporates or otherwise depends on patents, trade secrets or other proprietary intellectual property of third parties.
7.10 Licensee Warrants: (a) it has obtained all the necessary approvals and has or will make all the required disclosures necessary to enter into this Agreement; (b) has disposed of all debt and liabilities as of the effective date of this Agreement ; (c) has no current, pending or threatened litigation; (c) is current and in full compliance with all reporting requirements and applicable securities laws; (d) is fully authorized and legally capable of raising equity capital through issuance of common shares in amounts sufficient to fulfill obligations herein including the Merger; (e) following the Effective Date of this Agreement licensee will retain a law firm and an accountant firm suitable to Licensor; and (f) that an election for new officers and directors will occur within 30 days of the Effective Date of this Agreement and such officers and/or directors will have the prior approval of the Licensor.
9.1 No Warranties: LICENSOR MAKES NO WARRANTIES, EXPRESS OR IMPLIED, AS TO ANY MATTER WHATSOEVER NOT EXPRESSLY DEFINED HEREIN, INCLUDING, WITHOUT LIMITATION, THE RESULTS OF ANY CLINICAL TRIAL, PRODUCT COMMERCIALIZATION, OR ANY INVENTION, PROCESS, OR PRODUCT, WHETHER TANGIBLE OR INTANGIBLE, CONCEIVED, DISCOVERED, OR DEVELOPED BY LICENSOR. LICENSOR WILL NOT BE LIABLE FOR ANY INDIRECT, CONSEQUENTIAL, OR OTHER DAMAGES SUFFERED BY LICENSEE OR ANY SUBLICENSEE, OR ANY OTHERS INCLUDING, BUT NOT LIMITED TO, DAMAGES ARISING FROM LOSS OF DATA OR DELAY OR TERMINATION ANY CLINICAL TRIAL OR PRODUCT COMMERCIALIZATION, OR FROM THE USE OF THE RESULTS OF ANY CLINICAL TRIAL OR PRODUCT COMMERCIALIZATION, OR ANY SUCH INVENTION OR PRODUCT.
10.2 Licensor may terminate this Agreement upon written notice to Licensee if the Licensee makes a general assignment for the benefit of creditors, is the subject of proceedings in voluntary or involuntary bankruptcy or has a receiver or trustee appointed for substantially all of its property. Licensor may also terminate this agreement upon a change in control of Licensee unless such change of control is prior approved in writing by the Licensor. Similarly, Licensee may terminate this Agreement upon written notice to Licensor if the Licensor makes a general assignment for the benefit of creditors, is the subject of proceedings in voluntary or involuntary bankruptcy or has a receiver or trustee appointed for substantially all of its property.
10.4.1 The License granted to Licensee under Paragraph 2.1 is revoked and of no further force and effect. Licensee and any Sublicensee shall immediately cease any Commercialization of the Products and return to Licensor any Confidential Information or other material pertaining to the Patents or the Products in Licensee's possession or under Licensee's control (including any Confidential Information or material in the possession or under the control of any Sublicensee).
10.4.2 Licensor will continue to retain sole and exclusive ownership of any and all Patents, Products and all Intellectual Property therein or pertaining thereto and any Know-How.
10.4.3 Licensee’s confidentiality and non-use obligations will continue for a period of ten (10) years from the termination of this Agreement.
10.4.4 Licensee’s non-compete obligations will continue for a period of three (3) years from the termination of this Agreement.
10.4.5 Licensor’s no warranty and force majeure clauses under Paragraphs 9.1 and 9.2 will continue.
10.4.6 The Miscellaneous Provisions provided below in Paragraphs 11 will continue.
10.5 Credit for Payments. If either party terminates this Agreement or in the event of failure to consummate the Merger within 5 years, the total amount of funds paid by Licensee to Licensor, less any amounts obtained by Licensee as Sublicensee fees, at the date of termination shall be converted into equity of the Licensor to the Licensee. Licensor shall issue to Licensee ordinary shares. The shares will have the same proportional value as they would have had at the time of the Merger in paragraph 4.
11.1 Governing Authority: This Agreement will be governed by and construed in accordance with the laws of New York without reference to conflict of law principles. Any disputes under this Agreement may be brought in the courts located in New York, New York, and Licensee and Licensor consent to the personal jurisdiction and venue of these courts.
Notices to Licensor will be addressed as follows:
_________________________
Immunovative Therapies Ltd.
Malcha Technology Xxxx
Xxxxxxxx Xx. 0, Xxxxx Xxxxx,
Xxxxxxxxx, Xxxxxx, 00000
Facsimile No. x000-0-000-0000
Z. Xxxxx Xxxxxxx, Esq.
XXXXXXX, XXXXXXXX & XXXXX, P.A.
000 Xxxxxx Xxxxxx Xxxxx, Xxxxx 0000
Xxxxxxxxxxx, XX 00000, U.S.A.
Notices to Licensee will be addressed as follows:
_________________________
Novo Energies Corporation (or Immunovative, Inc. upon the legal name change)
000 Xxxx xx Xxxxx x'Xxxx, Xxxxx 00,
Xxxxxxxx, Xxxxxx, Xxxxxx X0X 0X0
Facsimile No. _________
IN WITNESS WHEREOF, Immunovative Therapies Ltd. and Novo Energies Corporation executed this Agreement on the respective dates indicated.
Dr. Michael Har-Noy, CEO
Immunovative Therapies Ltd.
Dec. 12, 2011
/s/ Xxxxxxxx Xxxxxxxx
Xxxxxxxx Xxxxxxxx
Novo Energies Corp.
Date: Dec. 9, 2011
Schedule A
I. U.S. Granted Patents:
|
1.
|
U.S. Patent No. 7,402,431, issued on July 22, 2008, and entitled “T-Cell Therapy Formulation”
|
|
2.
|
U.S. Patent No. 7,435,592, issued on October 14, 2008, and entitled “Compositions For Allogeneic Cell Therapy”
|
|
3.
|
U.S. Patent No. 7,592,431, issued on September 22, 2009, and entitled “Biodegradable T-Cell Activation Device”
|
|
4.
|
U.S. Patent No. 7,678,572, issued on March 16, 2010, and entitled “Methods For Preparing T-Cells For Cell Therapy”
|
|
5.
|
U.S. Patent No. 7,943,180, issued on May 17, 2011, and entitled “Method For Stimulating A Host Immune System By Administering An Allogeneic Cell Material”
|
|
6.
|
U.S. Patent No. 7,956,164, issued on June 7, 2011, and entitled “Device For Enhancing Immunostimulatory Capabilities Of T-Cells”
|
|
7.
|
U.S. Patent No. 7,972,594, issued on July 5, 2011, and entitled “Ablative Immunotherapy”
|
|
8.
|
U.S. Patent No. 8,012,750, issued on September 6, 2011, and entitled “T-Cell Activation Device”
|
|
9.
|
U.S. Patent No. 8,071,374, issued on December 6, 2011 and entitled “Method For Preparing T-Cells for Cell Therapy”
|
|
10.
|
U.S. Patent No. 8,076,135, issued on December 13, 2011 and entitled "Method of Preparing a Treatment Effective Amount of Allogeneic T-Cells"
|
|
1.
|
U.S. Patent Application No. 13/099,867, filed May 3, 2011, published as U.S. Publication No. 2011/0206707, and entitled “Method For Stimulating A Host Immune System”
|
|
2.
|
U.S. Patent Application No. 13/077,347, filed March 31, 2011, published as U.S. Publication No. 2011/0177596, and entitled “Device For Enhancing Immunostimulatory Capabilities Of T-Cells”
|
|
3.
|
U.S. Patent Application No. 12/967,910, filed December 14, 2010, published as U.S. Publication No. 2011/0142887, and entitled “Methods And Compositions For Liquidation Of Tumor”
|
|
4.
|
U.S. Patent Application No. 12/909,517, filed October 21, 2010, published as U.S. Publication No. 2011/0040259, and entitled “Method For Allogeneic Cell Therapy”
|
|
5.
|
U.S. Patent Application No. 12/887,054, filed September 21, 2010, published as U.S. Publication No. 2011/0033435, and entitled “Composition Of Activated CD4 Cells”
|
|
6.
|
U.S. Patent Application No. 12/887,039, filed September 21, 2010, published as U.S. Publication No. 2011/0028912, and entitled “Method To Formulate T-Cells”
|
|
7.
|
U.S. Patent Application No. 12/869,490, filed August 26, 2010, published as U.S. Publication No. 2010/0322966, and entitled “Method For Allogeneic Cell Therapy”
|
|
9.
|
U.S. Patent Application No. 12/570,442, filed September 30, 2009, published as U.S. Publication No. 2010/0086561, and entitled “Th1 Vaccination Priming For Active Immunotherapy”
|
|
10.
|
U.S. Patent Application No. 12/173,330, filed July 15, 2008, published as U.S. Publication No. 2008/0279836, and entitled “Method Of Making A Cell Therapy Formulation”
|
|
11.
|
U.S. Patent Application No. 11/936,221, filed November 7, 2007, published as U.S. Publication No. 2008/0112963, and entitled “Ablative Immunotherapy”
|
|
12.
|
U.S. Patent Application No. 11/251,585, filed October 14, 2005, published as U.S. Publication No. 2006/0115487, and entitled “Allogeneic Cellular Immunotherapy For Invasive Pulmonary Aspergillosis (IPA)”
|